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Summary	  
	  
Breastfeeding	  is	  a	  critical	  child	  survival	  intervention.	  The	  potential	  for	  transmission	  of	  some	  
viral	  infections	  from	  mother-­‐to-­‐child,	  however,	  presents	  the	  dilemma	  of	  how	  best	  to	  
interpret	  the	  benefits	  and	  risks	  of	  breastfeeding	  in	  different	  settings.	  Here,	  we	  compare	  the	  
transmission	  dynamics,	  risk	  factors	  and	  outcomes	  of	  infection	  with	  three	  chronic	  viruses	  
transmitted	  through	  breast	  milk:	  cytomegalovirus	  (CMV),	  human	  T-­‐cell	  lymphotropic	  virus	  
type	  1	  (HTLV-­‐1),	  and	  human	  immunodeficiency	  virus	  (HIV).	  We	  provide	  an	  overview	  of	  
current	  intervention	  approaches	  and	  discuss	  scientific,	  policy	  and	  programming	  gaps	  in	  our	  
understanding	  of	  these	  major	  global	  infections.	  	  
	  
Key	  messages:	  
• Three	  viruses	  are	  known	  to	  be	  transmitted	  through	  breastfeeding	  and	  to	  result	  in	  
chronic	  infection:	  CMV,	  HTLV-­‐1	  and	  HIV.	  
• CMV	  transmission	  through	  breast	  milk	  mostly	  leads	  to	  subclinical	  infection,	  except	  in	  
preterm	  infants	  in	  whom	  severe	  clinical	  disease	  can	  occur;	  the	  best	  preventive	  and	  
treatment	  approaches	  in	  this	  group	  remain	  unclear	  and	  more	  data	  are	  needed	  on	  
long-­‐term	  sequelae.	  
• HTLV-­‐1	  is	  restricted	  to	  specific	  geographic	  foci	  and	  can	  be	  transmitted	  from	  mother-­‐
to-­‐child	  through	  breastfeeding	  in	  10-­‐25%	  of	  cases;	  the	  best	  preventive	  strategy	  is	  
avoidance	  or	  shortening	  of	  breastfeeding	  where	  safe	  alternatives	  are	  available.	  
• The	  absolute	  transmission	  risk	  of	  HIV	  through	  breastfeeding	  in	  the	  context	  of	  
suppressive	  maternal	  antiretroviral	  therapy	  is	  now	  low,	  even	  over	  extended	  periods.	  
• Guidance	  for	  infant	  feeding	  for	  women	  living	  with	  HIV	  varies	  by	  setting:	  in	  low-­‐	  and	  
middle-­‐income	  countries,	  breastfeeding	  with	  suppressive	  ART	  and	  adherence	  
support	  is	  recommended,	  while	  in	  high-­‐income	  settings	  formula	  feeding	  is	  advised.	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Introduction	  
Optimal	  breastfeeding	  is	  a	  critical	  intervention	  in	  the	  quest	  to	  ensure	  that	  all	  children	  survive	  
and	  thrive1,	  2.	  Early	  breastfeeding	  within	  the	  first	  hour	  of	  birth	  and	  exclusive	  breastfeeding	  
(meaning	  no	  other	  food	  or	  liquids	  except	  prescribed	  medications)	  for	  six	  months,	  reduce	  all-­‐
cause	  under-­‐5-­‐year	  child	  mortality1,	  2.	  However,	  breastfeeding	  can	  also	  transmit	  infections.	  	  
Three	  viruses	  are	  of	  particular	  global	  importance,	  since	  they	  can	  be	  transmitted	  from	  
mother-­‐to-­‐child	  and	  lead	  to	  chronic	  infection:	  cytomegalovirus	  (CMV),	  Human	  T-­‐cell	  
Lymphotropic	  Virus	  type	  1	  (HTLV-­‐1)	  and	  Human	  Immunodeficiency	  Virus	  (HIV).	  Particularly	  
where	  prolonged	  breastfeeding	  for	  12-­‐24	  months	  postpartum	  is	  usual,	  this	  provides	  a	  long	  
duration	  of	  exposure	  to	  a	  potential	  source	  of	  infection	  and	  therefore	  presents	  a	  dilemma:	  
how	  best	  to	  interpret	  the	  benefits	  and	  risks	  of	  breastfeeding	  in	  different	  settings.	  In	  this	  
Review,	  we	  discuss	  the	  basic	  science,	  global	  public	  health	  approaches	  and	  policy	  gaps	  in	  our	  
understanding	  of	  mother-­‐to-­‐child	  transmission	  (MTCT)	  of	  these	  three	  viruses.	  
	  
Breastfeeding	  shapes	  infant	  development	  
Breast	  milk	  is	  more	  than	  just	  food:	  it	  contains	  a	  suite	  of	  beneficial	  components	  including	  
immunoglobulins,	  immune	  cells,	  stem	  cells,	  exosomes,	  growth	  factors,	  cytokines,	  lactoferrin	  
and	  oligosaccharides3.	  Breast	  milk	  is	  extraordinarily	  adaptive,	  and	  its	  composition	  is	  
governed	  by	  multiple	  factors	  including	  mode	  of	  delivery4,	  time	  from	  birth5,	  geography6,	  sex7	  
and	  infant	  illness8.	  The	  mother-­‐infant	  pair	  is	  intimately	  linked	  through	  breastfeeding.	  The	  
concept	  of	  a	  common	  maternal-­‐infant	  mucosal	  immune	  system9	  derives	  from	  observations	  
that	  B-­‐cells	  primed	  in	  the	  mother	  provide	  a	  source	  of	  infant	  immunoglobulins,	  and	  maternal	  
immune	  cells	  penetrate	  the	  infant	  gut	  to	  populate	  the	  newborn,	  providing	  long-­‐term	  
protection	  through	  a	  process	  termed	  maternal	  micro-­‐chimerism10,	  11.	  Breast	  milk	  contains	  a	  
rich	  microbial	  community12,	  helping	  to	  establish	  the	  infant	  intestinal	  microbiota,	  which	  is	  
further	  shaped	  by	  breast	  milk	  glycans	  such	  as	  human	  milk	  oligosaccharides13.	  Bacterial	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colonisation	  of	  the	  infant	  gut	  drives	  immune	  homeostasis	  and	  promotes	  intestinal	  
maturation,	  including	  production	  of	  the	  mucus	  layer,	  antimicrobial	  peptides	  and	  gut	  barrier	  
function14.	  	  
	  
While	  the	  mature	  gut	  constitutes	  a	  remarkable	  defence	  system,	  the	  young	  infant	  gut	  
remains	  vulnerable	  to	  infection	  during	  this	  dynamic	  period	  of	  intestinal	  adaptation.	  For	  
example,	  the	  newborn	  has	  increased	  intestinal	  permeability	  for	  several	  weeks	  after	  birth	  to	  
enable	  the	  process	  of	  maternal	  micro-­‐chimerism11,	  which	  might	  facilitate	  passage	  of	  cell-­‐
associated	  viruses	  in	  breast	  milk;	  there	  is	  relative	  achlorhydria	  in	  the	  stomach,	  which	  impairs	  
neutralisation	  of	  viruses15;	  and	  infants	  have	  a	  large	  population	  of	  intestinal	  CCR5+	  memory	  
CD4+	  T-­‐cells,	  which	  provide	  a	  highly	  susceptible	  pool	  of	  target	  cells	  for	  HIV16.	  Furthermore,	  
exposure	  to	  viruses	  in	  early	  life	  occurs	  at	  a	  time	  when	  anti-­‐viral	  immunity	  is	  not	  well	  
developed	  due	  to	  enhanced	  tolerogenic	  responses,	  reduced	  Th1	  development,	  and	  naïve	  
lymphocyte	  predominance;	  the	  capacity	  to	  control	  viral	  infections	  only	  matures	  over	  the	  
first	  few	  years17.	  	  However,	  any	  potential	  vulnerability	  associated	  with	  breastfeeding	  in	  the	  
context	  of	  maternal	  viral	  infections	  must	  be	  interpreted	  against	  the	  proven	  protection	  of	  
breastfeeding	  (Figure	  1).	  
	  
Mother-­‐to-­‐child	  transmission	  of	  viruses	  through	  breastfeeding	  
Three	  viruses	  are	  known	  to	  be	  transmitted	  through	  breastfeeding	  and	  to	  result	  in	  chronic	  
infection,	  with	  substantial	  clinical	  disease	  among	  some	  infants:	  CMV,	  HTLV-­‐1	  and	  HIV.	  By	  
contrast,	  despite	  being	  found	  in	  milk,	  breastfeeding	  does	  not	  increase	  the	  risk	  of	  mother-­‐to-­‐
child	  transmission	  for	  two	  other	  chronic	  viral	  infections	  of	  global	  importance,	  hepatitis	  B	  and	  
C18,	  19.	  	  The	  transmission	  dynamics	  and	  outcomes	  following	  MTCT	  are	  distinct	  for	  CMV,	  HLTV-­‐
1	  and	  HIV	  (Table	  1),	  and	  are	  influenced	  by	  maternal,	  infant,	  viral	  and	  environmental	  factors.	  	  
	  
	  	   7	  
CMV	  
CMV	  is	  a	  member	  of	  the	  ubiquitous	  Human	  Herpes	  Virus	  family;	  humans	  have	  been	  co-­‐
existing	  with	  these	  DNA	  viruses	  for	  millennia20.	  Primary	  CMV	  infection	  in	  the	  
immunocompetent	  host	  is	  usually	  subclinical	  and	  the	  virus	  then	  establishes	  lifelong	  latency,	  
with	  asymptomatic	  intermittent	  viral	  reactivation	  and	  excretion	  via	  body	  fluids21.	  	  Age	  at	  
CMV	  acquisition	  varies	  geographically:	  in	  high-­‐income	  countries,	  approximately	  5-­‐30%	  of	  
children	  are	  CMV-­‐seropositive	  by	  5-­‐6	  years	  of	  age,	  compared	  with	  85-­‐95%	  in	  low-­‐	  and	  
middle-­‐income	  countries	  (LMIC)21.	  In	  some	  LMIC,	  infection	  occurs	  almost	  universally	  during	  
infancy:	  in	  a	  Gambian	  study,	  for	  example,	  85%	  had	  acquired	  CMV	  by	  the	  age	  of	  12	  months22.	  
Worldwide,	  CMV	  seropositivity	  among	  women	  of	  reproductive	  age	  therefore	  ranges	  from	  
40-­‐100%,	  with	  higher	  seroprevalence	  in	  LMIC23.	  	  
	  
More	  than	  80%	  of	  seropositive	  women	  excrete	  CMV	  in	  breast	  milk24.	  Little	  or	  no	  virus	  is	  
detectable	  in	  colostrum,	  but	  CMV	  DNA	  is	  increasingly	  detected	  in	  breast	  milk	  to	  a	  maximum	  
level	  at	  4-­‐8	  weeks	  of	  lactation,	  with	  subsequent	  decline,	  often	  to	  minimal	  levels25.	  CMV-­‐
seropositive	  women	  also	  excrete	  virus	  in	  the	  birth	  canal,	  saliva	  and	  urine;	  thus	  the	  exact	  
route	  of	  early	  CMV	  transmission	  can	  be	  difficult	  to	  ascertain.	  CMV	  is	  excreted	  by	  mammary	  
epithelium	  and	  is	  found	  in	  both	  the	  milk	  whey	  and	  cellular	  (leukocyte)	  compartments;	  cell-­‐
free	  virus	  in	  the	  whey	  is	  associated	  with	  a	  higher	  vertical	  transmission	  risk26.	  Mothers	  with	  
earlier	  excretion	  of	  infectious	  virus,	  higher	  CMV	  milk	  viral	  loads	  and	  longer	  duration	  of	  
excretion,	  are	  more	  likely	  to	  transmit	  CMV26-­‐28.	  	  An	  intriguing	  recent	  study	  from	  Uganda	  
suggested	  that	  infant-­‐to-­‐mother	  transmission	  of	  CMV	  can	  also	  occur,	  such	  that	  infants	  first	  
acquire	  primary	  CMV,	  either	  from	  another	  child	  in	  the	  house	  or	  from	  their	  mother	  through	  
breastfeeding,	  and	  then	  transmit	  the	  infection	  to	  their	  mother29.	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Premature	  infants	  (<32	  weeks’	  gestation)	  are	  at	  risk	  of	  symptomatic	  postnatal	  CMV	  
infection24.	  The	  frequency	  of	  transmission	  and	  risk	  of	  clinical	  disease	  in	  preterm	  infants	  is	  
not	  well	  established,	  since	  most	  studies	  have	  small	  numbers,	  lack	  good	  control	  groups,	  and	  
report	  variable	  breast	  milk	  exposure	  durations.	  However,	  a	  meta-­‐analysis	  of	  695	  premature	  
infants	  breastfed	  by	  CMV-­‐seropositive	  mothers	  (17	  studies,	  median	  38	  infants	  per	  study,	  
range:	  7–90),	  found	  that	  CMV	  transmission	  ranged	  from	  2-­‐37%;	  CMV-­‐related	  symptoms	  
developed	  in	  0-­‐18%,	  and	  severe	  “sepsis-­‐like”	  symptoms	  in	  0-­‐14%	  of	  infants30.	  Among	  the	  
few	  studies	  reporting	  longer-­‐term	  follow-­‐up	  of	  premature	  infants	  (<1500g	  birth	  weight)	  with	  
postnatal	  CMV	  acquisition,	  some	  found	  no	  significant	  differences	  in	  outcomes	  compared	  to	  
controls,	  while	  others	  suggested	  mild	  neurocognitive	  impairments31-­‐33.	  Unlike	  congenital	  
CMV	  infection,	  no	  sensorineural	  hearing	  loss	  has	  been	  found31,	  33.	  	  	  
	  
CMV	  breast	  milk	  transmission	  is	  obviated	  by	  pasteurisation,	  but	  this	  negatively	  affects	  other	  
important	  breast	  milk	  components	  and	  is	  not	  feasible	  in	  many	  settings34.	  Freezing,	  
ultraviolet-­‐C	  irradiation	  and	  high-­‐power	  microwave	  reduce	  CMV	  viral	  load	  and	  thus	  
transmission,	  with	  less	  effect	  on	  other	  breast	  milk	  components,	  but	  more	  work	  is	  required	  
to	  ascertain	  the	  best	  treatment	  methodologies,	  especially	  in	  the	  context	  of	  milk	  banks	  for	  
preterm	  infants35-­‐37.	  One	  study	  suggested	  freezing	  may	  increase	  the	  risk	  of	  necrotising	  
enterocolitis,	  which	  has	  to	  be	  balanced	  with	  the	  risk	  of	  symptomatic	  CMV38.	  Some	  national	  
guidelines	  suggest	  pasteurisation	  of	  breast	  milk	  for	  extreme	  preterm	  infants	  born	  to	  CMV-­‐
seropositive	  mothers	  until	  around	  31	  weeks’	  gestation,	  aiming	  to	  reduce	  the	  risk	  of	  
transmission	  during	  the	  most	  vulnerable	  period39.	  	  	  
	  
Women	  living	  with	  HIV	  have	  a	  higher	  risk	  of	  transmitting	  CMV	  than	  women	  without	  HIV,	  due	  
to	  longer	  duration	  of	  CMV	  excretion	  and	  higher	  breast	  milk,	  cervical,	  and	  salivary	  CMV	  viral	  
loads40,	  41.	  In	  the	  only	  randomised	  controlled	  trial	  of	  breastfeeding	  versus	  formula	  feeding,	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conducted	  among	  mothers	  living	  with	  HIV	  in	  Nairobi	  during	  the	  pre-­‐antiretroviral	  therapy	  
(ART)	  era,	  a	  secondary	  analysis	  of	  CMV	  transmission	  was	  undertaken	  in	  138	  breastfed	  and	  
134	  formula-­‐fed	  infants42.	  Overall,	  breastfed	  infants	  acquired	  CMV	  earlier	  than	  formula-­‐fed	  
infants	  (median	  age,	  4.26	  vs	  9.87	  months;	  P<0.001)	  and	  had	  a	  higher	  1-­‐year	  probability	  of	  
CMV	  infection	  (0.89	  vs	  0.69;	  P<0.001),	  although	  the	  proportion	  with	  symptomatic	  infection	  
was	  not	  reported.	  The	  risk	  of	  infant	  CMV	  acquisition	  was	  1.6-­‐fold	  greater	  (95%	  conﬁdence	  
interval	  1.20,	  2.16;	  P=0.002)	  with	  breastfeeding,	  independent	  of	  infant	  HIV	  status.	  HIV-­‐
infected	  infants	  who	  acquire	  postnatal	  CMV	  can	  develop	  severe	  symptomatic	  disease,	  and	  
CMV	  is	  a	  co-­‐factor	  for	  HIV	  disease	  progression	  in	  some	  studies43.	  There	  is	  some	  evidence	  
that	  postnatal	  CMV	  may	  affect	  the	  immune	  development,	  growth	  and	  health	  of	  HIV-­‐exposed	  
uninfected	  infants,	  but	  more	  data	  are	  needed44.	  The	  impact	  of	  maternal	  ART	  on	  breast	  milk	  
CMV	  viral	  load	  and	  postnatal	  transmission	  risk	  is	  heterogeneous45-­‐47	  and	  it	  has	  been	  argued	  
that	  new	  approaches	  to	  reducing	  postnatal	  CMV	  transmission	  among	  HIV-­‐exposed	  infants	  
are	  needed44.	  
	  
Taken	  together,	  CMV	  transmission	  from	  mothers	  to	  infants	  occurs	  at	  high	  frequency	  and	  
very	  early	  in	  life,	  particularly	  in	  LMIC	  and	  among	  women	  living	  with	  HIV.	  Postnatal	  infection	  
in	  very	  preterm	  infants	  can	  cause	  clinical	  disease	  and	  strategies	  to	  prevent	  transmission	  
through	  breast	  milk	  are	  needed.	  Whether	  CMV	  transmission	  through	  breastfeeding	  needs	  to	  
be	  reduced	  in	  populations	  other	  than	  very	  preterm	  infants	  remains	  unclear.	  The	  available	  
evidence	  suggests	  that	  CMV	  infection	  in	  HIV-­‐unexposed	  term	  infants	  has	  limited	  clinical	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HTLV-­‐1	  
HTLV-­‐1,	  the	  first	  human	  retrovirus	  to	  be	  discovered	  in	  the	  early	  1980s48,	  infects	  at	  least	  5-­‐10	  
million	  people	  worldwide,	  mainly	  in	  highly	  focal	  endemic	  areas	  such	  as	  southern	  Japan,	  
West/Central	  Africa,	  the	  Caribbean	  and	  parts	  of	  South	  America	  and	  Australo-­‐Melanesia49.	  
Typically,	  adult	  prevalence	  in	  these	  endemic	  foci	  is	  around	  1-­‐2%,	  although	  up	  to	  20-­‐40%	  of	  
people	  aged	  over	  50	  years	  are	  living	  with	  HTLV-­‐1	  in	  some	  areas49.	  HTLV-­‐1	  preferentially	  
infects	  CD4+	  T-­‐cells,	  but	  CD8+	  T-­‐cells	  may	  also	  be	  important	  reservoirs;	  to	  a	  lesser	  extent,	  
monocytes,	  B-­‐cells,	  dendritic	  cells,	  and	  endothelial	  cells	  can	  be	  infected.	  Infection	  occurs	  by	  
transmission	  of	  HTLV-­‐1-­‐infected	  cells	  between	  individuals,	  through	  semen,	  blood,	  and	  breast	  
milk49.	  HTLV-­‐1	  infection	  is	  associated	  with	  two	  distinct	  diseases:	  a	  lymphoproliferative	  
disorder	  termed	  Adult	  T-­‐cell	  Leukaemia/Lymphoma	  (ATL),	  and	  an	  inflammatory	  neurological	  
disease	  called	  tropical	  spastic	  paraparesis	  or	  HTLV-­‐1-­‐associated	  myelopathy	  (TSP/HAM).	  
Acquisition	  of	  HTLV-­‐1	  during	  childhood	  is	  a	  major	  risk	  factor	  for	  the	  development	  of	  ATL50,	  
which	  has	  a	  median	  age	  at	  diagnosis	  of	  around	  50	  years	  and	  usually	  runs	  a	  very	  aggressive	  
course:	  the	  median	  survival	  in	  a	  case	  series	  from	  Jamaica	  was	  only	  20	  weeks51.	  Despite	  
improvement	  in	  treatment	  approaches,	  the	  acute	  and	  lymphoma	  types	  of	  ATL	  still	  have	  a	  
poor	  prognosis,	  with	  a	  4-­‐year	  survival	  of	  11-­‐16%	  in	  Japan	  between	  2000-­‐200952.	  TSP/HAM	  
typically	  has	  an	  insidious	  onset	  in	  adulthood,	  with	  sensory	  and	  bladder	  disturbance,	  together	  
with	  slowly	  progressive	  pyramidal	  signs;	  however,	  a	  case	  series	  of	  children	  with	  early-­‐onset	  
disease	  in	  Bahia,	  Brazil	  was	  recently	  reported53.	  HTLV-­‐1	  is	  also	  associated	  with	  other	  
inflammatory	  diseases	  such	  as	  infective	  dermatitis	  (mainly	  in	  children),	  uveitis	  and	  myositis.	  	  
	  
MTCT	  of	  HTLV-­‐1	  occurs	  in	  10-­‐25%	  of	  breastfed	  infants49.	  Based	  on	  epidemiological,	  
virological	  and	  experimental	  data,	  risk	  factors	  for	  MTCT	  have	  now	  been	  established.	  First,	  
transmission	  of	  HTLV-­‐1	  increases	  with	  longer	  duration	  of	  breastfeeding:	  for	  example,	  in	  a	  
prospective	  birth	  cohort	  in	  Jamaica,	  followed	  to	  at	  least	  2	  years	  of	  age,	  19/60	  (32%)	  children	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who	  breastfed	  for	  longer	  than	  12	  months	  acquired	  HTLV-­‐1,	  compared	  to	  8/86	  (9%)	  children	  
who	  breastfed	  for	  less	  than	  12	  months54.	  Second,	  higher	  HTLV-­‐1	  proviral	  load	  in	  maternal	  
blood	  and	  breast	  milk	  increases	  MTCT55,	  56.	  The	  proviral	  load	  is	  a	  proxy	  for	  the	  number	  of	  
infected	  cells,	  and	  reflects	  the	  fact	  that	  HTLV-­‐1	  transmission	  is	  cell-­‐associated,	  and	  not	  due	  
to	  cell-­‐free	  virus.	  A	  recent	  longitudinal	  study	  showed	  that	  the	  proviral	  load	  is	  stable	  during	  
pregnancy	  but	  elevated	  after	  delivery57.	  	  Finally,	  higher	  HTLV-­‐1	  antibody	  titres	  in	  maternal	  
blood	  are	  associated	  with	  increased	  MTCT	  risk,	  which	  may	  partly	  reflect	  the	  correlation	  
between	  antibody	  titres	  and	  maternal	  proviral	  load56.	  The	  processes	  underlying	  MTCT	  of	  
HTLV-­‐1	  remain	  largely	  unknown,	  although	  potential	  mechanisms	  have	  recently	  been	  
reviewed	  in	  detail58.	  	  	  
As	  there	  is	  no	  vaccine,	  and	  no	  antiretroviral	  regimen	  has	  been	  evaluated	  for	  PMTCT	  (or	  
adult-­‐to-­‐adult	  transmission),	  the	  only	  preventive	  strategy	  is	  for	  mothers	  living	  with	  HTLV-­‐1	  
to	  avoid	  breastfeeding.	  This	  approach	  has	  led	  to	  huge	  reductions	  in	  HTLV-­‐1	  MTCT	  in	  Japan.	  
For	  example,	  in	  the	  Nagasaki	  Prefecture,	  the	  introduction	  of	  exclusive	  formula	  feeding	  was	  
associated	  with	  a	  reduction	  of	  MTCT	  from	  20.3%	  to	  2.5%59.	  	  However,	  universal	  antenatal	  
screening	  is	  currently	  only	  undertaken	  in	  Japan.	  In	  a	  recent	  open	  letter	  to	  the	  WHO60,	  
experts	  have	  argued	  strongly	  for	  more	  action	  to	  prevent	  HLTV-­‐1,	  including	  routine	  antenatal	  
testing	  and	  avoidance	  or	  shortening	  of	  breastfeeding	  among	  mothers	  living	  with	  HTLV-­‐1	  
where	  safe,	  alternative	  methods	  of	  infant	  feeding	  are	  available.	  Further	  research	  is	  needed	  
to	  inform	  alternative	  approaches,	  including	  the	  role	  of	  maternal	  and/or	  infant	  antiretroviral	  
prophylaxis	  in	  reducing	  HTLV-­‐1	  MTCT.	  
	  
HIV	  
In	  2017,	  36.9	  million	  people	  globally	  were	  living	  with	  HIV,	  of	  whom	  1.8	  million	  were	  
children61.	  Despite	  the	  enormous	  impact	  of	  PMTCT	  interventions,	  which	  have	  averted	  an	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estimated	  1.4	  million	  new	  paediatric	  infections	  since	  2010,	  around	  180,000	  children	  
acquired	  HIV	  in	  201761.	  In	  the	  absence	  of	  any	  preventive	  interventions,	  transmission	  of	  HIV	  
by	  breastfeeding	  is	  estimated	  to	  be	  0.74%	  per	  month	  of	  breastfeeding62	  and	  contributes	  
around	  one-­‐third	  of	  the	  overall	  MTCT	  risk63;	  the	  relative	  contribution	  of	  postnatal	  
transmission	  has	  increased	  in	  most	  breastfeeding	  countries	  following	  the	  increased	  coverage	  
of	  antenatal	  PMTCT	  interventions64.	  	  
	  
Cell-­‐free	  and	  cell-­‐associated	  viral	  loads	  in	  milk	  are	  major	  determinants	  of	  transmission65;	  
other	  risk	  factors	  include	  the	  duration	  of	  breastfeeding62,	  severity	  of	  maternal	  
immunodeficiency62,	  maternal	  immune	  response	  to	  HIV66,	  presence	  of	  an	  inflammatory	  
process	  in	  the	  mammary	  gland	  (engorgement,	  mastitis,	  breast	  abscess)67,	  and	  early	  
introduction	  of	  non-­‐breast	  milk	  feeds	  (mixed	  feeding)68.	  With	  effective	  maternal	  HIV	  
suppression	  on	  ART,	  the	  absolute	  transmission	  risk,	  even	  over	  extended	  periods,	  is	  less	  than	  
1%	  in	  trial	  settings69,	  70.	  However,	  the	  risk	  of	  postnatal	  transmission	  is	  extremely	  high	  
(approximately	  30%)	  if	  the	  mother	  acquires	  HIV	  while	  breastfeeding71,	  particularly	  among	  
young	  infants,	  in	  whom	  the	  combination	  of	  high	  maternal	  HIV	  viral	  load	  and	  immature	  
intestinal	  integrity	  may	  increase	  susceptibility	  to	  transmission71.	  
	  
HIV	  actively	  replicates	  and	  produces	  viral	  particles	  during	  the	  whole	  duration	  of	  infection	  in	  
adults,	  particularly	  in	  sub-­‐mucosal	  compartments,	  which	  are	  rich	  in	  lymphoid	  cells72.	  	  HIV	  
transmission	  can	  therefore	  arise	  from	  both	  cell-­‐free	  and	  cell-­‐associated	  reservoirs	  in	  breast	  
milk73.	  Compared	  with	  lymphoid	  cells	  from	  blood,	  breast	  milk	  cells	  are	  more	  frequently	  
activated	  memory	  cells,	  which	  express	  homing	  markers	  indicating	  their	  mucosal	  origin74.	  
Quiescent	  CD4+	  T-­‐cells	  infected	  with	  HIV	  are	  also	  present	  in	  breast	  milk;	  if	  activated	  ex	  vivo,	  
these	  cells	  are	  much	  more	  capable	  of	  producing	  infectious	  particles	  than	  corresponding	  
blood	  cells74.	  In	  vivo,	  the	  activators	  of	  these	  quiescently	  infected	  cells	  may	  be	  co-­‐infections,	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since	  CMV	  and	  Epstein	  Barr	  virus	  DNA	  in	  milk	  are	  associated	  with	  shedding	  of	  HIV	  virions75.	  
In	  addition,	  activated	  CD4+	  T-­‐cells	  with	  actively	  replicating	  HIV	  can	  be	  identified	  in	  breast	  
milk	  of	  mothers	  on	  ART	  despite	  an	  undetectable	  plasma	  HIV	  viral	  load74.	  This	  activated	  
reservoir	  may	  be	  particularly	  prone	  to	  cell-­‐to-­‐cell	  transfer	  of	  HIV	  in	  the	  infant,	  providing	  a	  
residual	  source	  of	  postnatal	  transmission	  risk	  despite	  suppressive	  maternal	  ART64.	  Other	  cell	  
types,	  such	  as	  macrophages	  and	  dendritic	  cells,	  may	  also	  be	  involved	  in	  the	  establishment	  of	  
HIV	  reservoirs	  in	  the	  mammary	  gland	  and	  breast	  milk.	  Maternal	  micro-­‐chimerism	  through	  
breastfeeding,	  which	  seeds	  long-­‐lived	  maternal	  cells	  into	  infant	  tissues,	  may	  include	  cells	  
infected	  with	  HIV	  such	  as	  CD4+	  progenitor	  T-­‐cells,	  and	  may	  therefore	  represent	  an	  
additional	  source	  of	  HIV	  transmission10,	  11.	  
	  
Preventing	  breast	  milk	  HIV	  transmission	  in	  LMIC	  settings	  
Prior	  to	  availability	  of	  ART	  in	  LMIC	  settings,	  WHO	  recommended	  counselling	  of	  individual	  
mothers	  living	  with	  HIV	  to	  choose	  between	  replacement	  feeding	  or	  breastfeeding,	  
considering	  their	  living	  conditions	  and	  what	  method	  of	  feeding	  would	  most	  likely	  result	  in	  
their	  infants	  surviving	  while	  remaining	  HIV-­‐uninfected76,	  77.	  Recommendations	  changed	  in	  
2010	  following	  studies	  showing	  that	  ART	  significantly	  reduced	  HIV	  transmission	  risk,	  
together	  with	  reports	  of	  increased	  mortality,	  morbidity	  and	  growth	  failure	  due	  to	  
gastroenteritis	  and	  malnutrition	  among	  infants	  given	  replacement	  feeds	  as	  an	  HIV	  
prevention	  strategy78,	  79.	  There	  was	  increasing	  recognition	  that	  improving	  HIV-­‐free	  survival,	  
rather	  than	  preventing	  vertical	  HIV	  transmission	  alone,	  was	  the	  ultimate	  goal	  of	  PMTCT	  
programmes.	  Consequently,	  the	  2010	  WHO	  recommendations	  introduced	  infant	  post-­‐
exposure	  prophylaxis	  throughout	  breastfeeding	  (PMTCT	  Option	  A)	  or	  maternal	  triple	  ART	  
(PMTCT	  Option	  B)	  for	  HIV-­‐exposed	  breastfeeding	  infants	  whose	  mothers	  were	  not	  receiving	  
ART	  for	  their	  own	  health80.	  Within	  two	  years,	  these	  recommendations	  were	  rapidly	  adopted	  
into	  policy	  in	  the	  vast	  majority	  of	  high	  HIV	  prevalence	  LMIC.	  Ministries	  of	  Health	  and	  local	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communities	  had	  been	  grappling	  with	  the	  dilemma	  of	  preventing	  postnatal	  transmission	  
without	  undermining	  breastfeeding	  as	  a	  child	  survival	  strategy;	  a	  public	  health	  approach	  of	  
providing	  ART	  to	  all	  pregnant	  and	  lactating	  mothers	  living	  with	  HIV	  and	  recommending	  
breastfeeding	  addressed	  these	  competing	  demands.	  	  Yet,	  even	  in	  these	  settings,	  it	  was	  
noted	  that	  the	  2010	  WHO	  recommendations	  were	  not	  always	  “…translated	  into	  action	  by…	  
front-­‐line	  workers	  because	  of	  a	  variety	  of	  structural	  and	  ideological	  barriers”81.	  
	  
In	  2012,	  WHO	  guidelines	  recommended	  lifelong	  ART	  (referred	  to	  as	  Option	  B+)	  for	  all	  
pregnant	  and	  breastfeeding	  women	  to	  simplify	  interventions	  and	  to	  amplify	  the	  gains	  
beyond	  PMTCT,	  including	  preventing	  horizontal	  HIV	  transmission	  and	  protecting	  future	  
pregnancies82.	  ART	  is	  now	  recommended	  for	  adults	  and	  children	  from	  the	  time	  of	  
diagnosis83.	  As	  a	  result	  of	  these	  changes,	  multiparous	  mothers	  are	  now	  more	  likely	  to	  
conceive	  on	  ART,	  nulliparous	  pregnant	  women	  more	  likely	  to	  initiate	  ART	  earlier	  in	  
pregnancy,	  and	  breastfeeding	  mothers	  are	  more	  likely	  to	  be	  on	  ART.	  This	  earlier	  and	  
increased	  antiretroviral	  use	  provides	  a	  platform	  for	  maternal	  viral	  load	  suppression	  and	  for	  
eliminating	  mother-­‐to-­‐child	  HIV	  transmission	  (EMTCT),	  defined	  as	  <5%	  MTCT	  and	  ≤50	  new	  
paediatric	  HIV	  infections	  per	  100,000	  live	  births84.	  Although	  these	  updated	  policies	  have	  set	  
the	  scene	  for	  EMTCT,	  data	  from	  LMIC	  indicate	  poor	  retention	  in	  care	  and	  ART	  adherence	  
(73-­‐76%	  antenatal	  adherence,	  falling	  to	  55-­‐65%	  postnatally)85-­‐87.	  Although	  viral	  load	  
monitoring	  during	  pregnancy,	  delivery	  and	  breastfeeding	  is	  gaining	  momentum,	  it	  is	  not	  yet	  
fully	  integrated	  into	  routine	  care.	  Furthermore,	  although	  there	  is	  a	  correlation	  between	  
plasma	  and	  breast	  milk	  viral	  loads,	  an	  undetectable	  plasma	  HIV	  viral	  load	  does	  not	  indicate	  
lack	  of	  HIV	  infectivity,	  due	  to	  activated	  latent	  CD4+	  T-­‐cells	  in	  breast	  milk,	  even	  in	  the	  
presence	  of	  antiretroviral	  drugs.	  Whilst	  ART	  for	  mothers	  living	  with	  HIV	  or	  extended	  
prophylaxis	  for	  their	  infants	  in	  a	  clinical	  trial	  setting	  can	  reduce	  MTCT	  to	  <1%	  at	  1-­‐2	  years	  of	  
age69,	  70,	  these	  results	  are	  not	  easily	  reproducible	  in	  real-­‐life	  LMIC	  settings.	  The	  challenges	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posed	  by	  inadequate	  maternal	  adherence,	  irregular	  virological	  monitoring,	  uncertain	  
implications	  of	  low-­‐level	  viraemia	  for	  MTCT,	  and	  residual	  breast	  milk	  infectivity,	  question	  the	  
feasibility	  of	  eliminating	  breastfeeding	  MTCT	  in	  LMIC	  using	  present	  antiretroviral	  regimens.	  
Thus,	  the	  evaluation	  of	  combination	  strategies,	  including	  maternal	  ART	  with	  support	  for	  
adherence	  and	  maternal	  and/or	  infant	  passive	  immunoprophylaxis	  or	  active	  vaccination	  is	  a	  
research	  priority.	  
	  
Breastfeeding	  and	  HIV	  in	  high-­‐income	  settings	  
Avoidance	  of	  breastfeeding	  was	  the	  first	  effective	  PMTCT	  intervention	  for	  HIV	  in	  high-­‐
income	  countries.	  Based	  on	  a	  single	  case	  of	  transmission	  following	  transfusion-­‐acquired	  
postpartum	  HIV	  infection88	  and	  detection	  of	  HIV-­‐1	  in	  breast	  milk89,	  the	  first	  United	  States	  
Centers	  for	  Disease	  Control	  and	  Prevention	  recommendation	  to	  undertake	  exclusive	  formula	  
feeding	  was	  published	  in	  198590,	  and	  has	  been	  a	  core	  component	  of	  PMTCT	  guidelines	  in	  
high-­‐income	  countries	  ever	  since.	  Consequently,	  postpartum	  HIV	  MTCT	  in	  high-­‐income	  
countries	  is	  rare,	  and	  placing	  an	  infant	  at	  risk	  of	  HIV	  infection	  through	  breastfeeding	  has	  
been	  considered	  a	  child	  protection	  issue	  in	  some	  settings91.	  
	  
In	  2009-­‐2010,	  findings	  from	  several	  observational	  studies92-­‐94	  and	  two	  randomised	  trials95,	  96	  
highlighted	  the	  low	  rates	  of	  HIV	  transmission	  associated	  with	  breastfeeding	  in	  the	  context	  of	  
either	  maternal	  combination	  ART	  or	  infant	  prophylaxis	  with	  nevirapine	  or	  other	  
antiretroviral	  drugs.	  Guidelines	  in	  high-­‐income	  countries	  have	  continued	  to	  recommend	  
exclusive	  formula	  feeding	  regardless	  of	  maternal	  HIV	  viral	  load	  or	  therapy,	  since	  even	  with	  a	  
consistently	  undetectable	  maternal	  viral	  load,	  the	  MTCT	  risk	  is	  low	  but	  not	  negligible.	  
However,	  there	  has	  been	  a	  subtle	  but	  important	  shift	  in	  advice	  in	  high-­‐income	  settings	  since	  
these	  trial	  findings;	  for	  example,	  British	  HIV	  Association	  (BHIVA)	  guidelines	  in	  2010	  stated	  
that	  “…if	  a	  woman	  is	  on	  effective	  HAART	  and	  has	  compelling	  reasons	  to	  breastfeed,	  she	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should	  be	  supported	  to	  do	  so	  as	  safely,	  and	  for	  as	  short	  a	  period	  as	  possible”.	  Current	  BHIVA	  
guidelines97	  continue	  to	  recommend	  formula	  feeding,	  but	  provide	  advice	  regarding	  clinical	  
and	  laboratory	  monitoring	  for	  women	  who	  decide	  to	  breastfeed	  after	  evidence-­‐based	  
counselling,	  similar	  to	  European98	  and	  US99	  guidelines.	  	  
	  
In	  the	  context	  of	  sexual	  transmission,	  an	  undetectable	  viral	  load	  is	  now	  considered	  to	  
indicate	  that	  HIV	  is	  untransmittable	  (so-­‐called	  “U=U”).	  However,	  a	  similar	  confidence	  has	  not	  
permeated	  the	  PMTCT	  context,	  for	  several	  possible	  reasons.	  There	  is	  a	  lack	  of	  data	  on	  
transmission	  risk	  to	  provide	  accurate	  information	  to	  mothers;	  concerns	  regarding	  maternal	  
adherence	  to	  ART;	  the	  potential	  for	  local	  HIV	  replication	  in	  the	  breast	  during	  episodes	  of	  
mastitis;	  uncertainty	  regarding	  the	  impact	  of	  low-­‐dose	  exposure	  to	  ART	  through	  breast	  milk;	  
and	  intense	  monitoring	  is	  required	  during	  breastfeeding.	  High-­‐quality	  evidence	  is	  therefore	  
still	  needed	  to	  inform	  these	  issues	  and	  to	  guide	  recommendations	  on	  infant	  feeding	  by	  
mothers	  living	  with	  HIV.	  
	  
Exposure	  to	  antiretroviral	  drugs	  through	  breastfeeding	  
Since	  current	  guidelines	  recommend	  that	  mothers	  living	  with	  HIV	  in	  LMIC	  undertake	  
prolonged	  breastfeeding	  on	  ART83,	  it	  is	  essential	  to	  quantify	  the	  clinical	  importance	  of	  any	  
adverse	  effects	  of	  infant	  ART	  exposure	  through	  breast	  milk.	  Factors	  influencing	  drug	  
exposure	  in	  breastfed	  infants	  are	  shown	  in	  Figure	  2.	  The	  peak	  concentrations	  of	  ART	  in	  
breast	  milk	  lag	  behind	  those	  for	  plasma,	  and	  the	  elimination	  phase	  may	  be	  prolonged;	  such	  
kinetics	  are	  seen	  for	  the	  nucleoside	  reverse	  transcriptase	  inhibitors	  (NRTIs)100.	  Exclusively	  
breastfed	  infants	  receive	  up	  to	  10%	  of	  the	  weight-­‐adjusted	  infant	  dose	  of	  NRTIs	  and	  non-­‐
NRTIs	  (NNRTIs)	  whereas	  protease	  inhibitors	  have	  little	  transfer	  to	  the	  infant101.	  Genetic	  
differences,	  such	  as	  CYP2B6	  polymorphisms	  in	  the	  case	  of	  efavirenz,	  result	  in	  higher	  infant	  
drug	  exposure102.	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The	  major	  potential	  risk	  to	  the	  infant	  from	  exposure	  to	  maternal	  ART	  through	  breastfeeding	  
is	  toxicity.	  However,	  it	  can	  be	  difficult	  to	  distinguish	  the	  effects	  of	  in	  utero	  and	  breast	  milk	  
exposure	  to	  a	  drug.	  There	  has	  been	  considerable	  debate	  about	  the	  effects	  of	  infant	  exposure	  
to	  tenofovir,	  although	  a	  recent	  systematic	  review	  suggests	  changes	  in	  bone	  mineral	  density	  
have	  no	  clinical	  relevance103.	  Dolutegravir	  is	  the	  first	  integrase	  strand-­‐transfer	  inhibitor	  to	  be	  
studied	  in	  breastfeeding	  mother-­‐infant	  pairs,	  and	  is	  measurable	  in	  both	  breast	  milk	  and	  the	  
plasma	  of	  the	  breastfed	  infant104,	  but	  the	  clinical	  consequences	  are	  currently	  uncertain.	  
Pharmacovigilance	  among	  infants	  exposed	  to	  drugs	  through	  breastfeeding	  is	  not	  well	  
established,	  with	  under-­‐reporting	  of	  adverse	  drug	  reactions,	  and	  a	  likely	  skew	  towards	  the	  
most	  serious	  events105.	  Whilst	  few	  studies	  have	  systematically	  collected	  infant	  safety	  data,	  
the	  recent	  PROMISE	  trial	  showed	  no	  increase	  in	  toxicities	  among	  infants	  exposed	  to	  ART	  
through	  breast	  milk,	  compared	  to	  extended	  infant	  nevirapine	  prophylaxis69.	  Whilst	  the	  
Antiretroviral	  Pregnancy	  Registry	  is	  well	  established,	  no	  parallel	  system	  exists	  to	  
systematically	  collect	  data	  on	  clinical	  outcomes,	  growth	  and	  development	  in	  breastfed	  
infants.	  Furthermore,	  the	  clinical	  tools	  needed	  to	  identify	  subtle	  toxicities	  have	  not	  been	  
established.	  
	  
Breast	  milk	  ART	  exposure	  may	  increase	  the	  risk	  of	  drug	  resistance	  among	  infants	  who	  
acquire	  HIV.	  Secondary	  analysis	  of	  two	  large	  PMTCT	  trials	  indicated	  that,	  although	  MTCT	  
rates	  were	  very	  low,	  infants	  who	  acquired	  HIV	  during	  breastfeeding	  while	  their	  mother	  was	  
receiving	  ART	  had	  high	  rates	  (75-­‐100%)	  of	  multi-­‐class	  drug	  resistance,	  defined	  as	  resistance	  
to	  both	  NRTIs	  and	  NNRTIs106,	  107.	  Analysis	  of	  mother-­‐infant	  pairs	  indicated	  that	  resistance	  
arose	  in	  the	  infant	  as	  a	  result	  of	  selective	  drug	  pressure108.	  This	  risk	  likely	  remains	  in	  
breastfeeding	  mothers	  who	  have	  poor	  adherence	  to	  therapy	  and	  is	  a	  potential	  challenge	  for	  
future	  first-­‐line	  treatment	  options	  among	  infants	  and	  young	  children.	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An	  emerging	  clinical	  challenge	  is	  the	  impact	  of	  infant	  exposure	  to	  maternal	  ART,	  including	  
during	  breastfeeding,	  on	  the	  accuracy	  of	  current	  early	  infant	  diagnosis	  protocols.	  Analysis	  of	  
more	  than	  13,000	  HIV-­‐exposed	  South	  African	  infants	  indicates	  an	  increase	  in	  equivocal	  
results	  since	  2015	  among	  infants	  who	  are	  later	  confirmed	  as	  HIV-­‐infected,	  in	  parallel	  with	  
the	  change	  in	  guidelines	  to	  lifelong	  maternal	  ART	  and	  increased	  duration	  of	  breastfeeding.	  
Maternal	  ART	  may	  reduce	  levels	  of	  infant	  viraemia	  and	  hence	  impair	  detection	  of	  HIV	  by	  
PCR109.	  This	  warrants	  further	  evaluation	  programmatically.	  
	  
Breast	  milk	  transmission	  of	  HIV:	  unknowns	  and	  future	  directions	  	  
The	  ultimate	  goal	  of	  policies	  and	  programmes	  to	  prevent	  postnatal	  HIV	  transmission	  is	  for	  
mothers	  to	  breastfeed	  their	  infants	  without	  consideration	  of	  their	  HIV	  status;	  three	  areas	  of	  
research	  therefore	  remain	  essential.	  First,	  there	  is	  a	  need	  to	  improve	  the	  efficacy,	  flexibility	  
and	  safety	  of	  ART	  regimens.	  Currently	  available	  interventions	  have	  transformed	  the	  
landscape	  for	  infant	  and	  young	  child	  feeding	  in	  the	  context	  of	  HIV	  but	  they	  could	  be	  
improved.	  Determining	  the	  most	  effective	  maternal	  and/or	  infant	  ART	  regimens	  during	  
breastfeeding,	  while	  decreasing	  their	  adverse	  effects,	  will	  help	  increase	  coverage	  and	  bring	  
transmission	  rates	  closer	  to	  zero.	  Second,	  learning	  how	  to	  identify	  all	  mothers	  living	  with	  HIV	  
(especially	  those	  infected	  postpartum)	  and	  evaluating	  pre-­‐exposure	  prophylaxis	  strategies	  to	  
reduce	  incident	  infection	  during	  breastfeeding	  remains	  pivotal.	  Third,	  facility-­‐	  and	  
community-­‐based	  interventions	  are	  needed	  to	  increase	  rates	  of	  retention-­‐in-­‐care	  of	  
mothers,	  regardless	  of	  feeding	  practice.	  In	  Malawi,	  effective	  peer	  support	  increased	  
postnatal	  retention	  in	  care	  and	  associated	  ART	  adherence	  to	  over	  80%	  at	  24	  months	  with	  
improved	  viral	  suppression	  and	  reduced	  resistance110.	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As	  women	  living	  with	  HIV	  in	  high-­‐income	  settings	  question	  their	  eligibility	  to	  breastfeed,	  and	  
women	  in	  LMIC	  are	  currently	  advised	  to	  breastfeed	  without	  effective	  counselling	  on	  risks,	  
the	  ethics	  of	  policies	  that	  argue	  for	  or	  against	  breastfeeding	  and	  the	  rights	  of	  women	  to	  
choose	  an	  infant	  feeding	  practice	  need	  examination.	  Breastfeeding	  in	  the	  context	  of	  HIV	  has	  
been	  a	  highly	  contested	  and	  divisive	  issue,	  often	  splitting	  the	  HIV	  and	  maternal-­‐child	  health	  
(MCH)	  communities.	  The	  integration	  of	  HIV-­‐specific	  interventions	  into	  facility-­‐	  and	  
community-­‐based	  MCH	  services	  is	  now	  a	  realistic	  policy	  and	  programme	  option;	  it	  is	  also	  an	  
imperative	  as	  funding	  streams	  call	  for	  greater	  efficiencies.	  	  
	  
Conclusions	  
Breastfeeding	  remains	  critical	  to	  child	  survival	  globally.	  Recent	  insights	  into	  the	  science	  of	  
breastfeeding,	  including	  the	  complex	  and	  adaptive	  properties	  of	  breast	  milk	  and	  the	  long-­‐
term	  benefits	  from	  its	  diverse	  range	  of	  constituents,	  demonstrate	  the	  importance	  of	  
continuing	  to	  apply	  modern	  tools	  to	  an	  ancient	  and	  highly	  evolved	  practice.	  However,	  the	  
risk	  of	  transmission	  through	  breastfeeding	  of	  three	  chronic	  viral	  infections	  of	  global	  health	  
importance	  (CMV,	  HTLV-­‐1	  and	  HIV)	  has	  implications	  for	  public	  health	  policy.	  CMV	  
transmission	  through	  breast	  milk	  is	  mostly	  of	  concern	  for	  preterm	  infants	  (<32	  weeks	  or	  
<1500g	  birth	  weight)	  in	  whom	  severe	  clinical	  disease	  can	  occur.	  However,	  the	  best	  
prevention	  and	  treatment	  approaches	  are	  currently	  uncertain,	  meaning	  practice	  varies	  
across	  settings,	  and	  further	  data	  are	  needed	  on	  long-­‐term	  sequelae.	  MTCT	  of	  HTLV-­‐1,	  which	  
is	  restricted	  to	  specific	  geographic	  foci,	  can	  be	  prevented	  by	  avoiding	  or	  shortening	  
breastfeeding,	  provided	  safe	  alternatives	  are	  available.	  Guidelines	  for	  infant	  feeding	  by	  
mothers	  living	  with	  HIV	  vary	  by	  setting:	  in	  LMICs,	  breastfeeding	  with	  maternal	  ART	  and	  
adherence	  support	  is	  the	  recommended	  approach,	  while	  in	  high-­‐income	  countries,	  exclusive	  
formula	  feeding	  is	  advised,	  although	  some	  women	  on	  suppressive	  ART	  are	  now	  choosing	  to	  
breastfeed.	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There	  are	  some	  remaining	  gaps	  in	  our	  understanding	  of	  the	  transmission	  dynamics	  and	  
potential	  interventions	  to	  reduce	  MTCT	  for	  these	  viruses	  	  (Panel).	  However,	  HIV	  is	  an	  
excellent	  example	  of	  how	  our	  knowledge	  of	  viral	  kinetics	  and	  interventions	  has	  advanced	  
since	  the	  virus	  was	  first	  identified	  in	  breast	  milk	  in	  198589,	  and	  how	  this	  understanding	  has	  
impacted	  public	  health	  interventions	  for	  children.	  Research	  remains	  an	  essential	  mechanism	  
for	  informing	  global	  guidelines	  and	  national	  policies	  and	  identifying	  viable	  options	  for	  
intervention	  to	  maximize	  the	  benefits	  of	  breastfeeding	  while	  minimising	  the	  risks	  of	  viral	  
transmission,	  to	  promote	  child	  health,	  development	  and	  long-­‐term	  human	  capital.	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Search	  strategy	  and	  selection	  criteria	  
References	  for	  this	  Review	  were	  initially	  identified	  by	  each	  author	  based	  on	  their	  knowledge	  
of	  the	  field.	  In	  addition,	  we	  searched	  PubMed	  using	  the	  search	  terms	  “CMV”,	  “HTLV-­‐1”,	  
“HIV”,	  “infant”	  and	  “breastfeeding”	  to	  identify	  additional	  studies,	  published	  in	  English,	  from	  
inception	  up	  to	  6th	  November	  2018.	  The	  final	  reference	  list	  was	  generated	  based	  on	  
inclusion	  of	  historical	  landmark	  studies,	  originality	  and	  relevance	  to	  the	  broad	  scope	  of	  this	  
Review.	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Figure	  legends	  
	  
Figure	  1:	  Balancing	  the	  benefits	  and	  risks	  of	  breastfeeding	  in	  the	  context	  of	  breast	  milk	  viral	  
transmission.	  
	  
Figure	  2:	  	  Factors	  influencing	  drug	  exposure	  in	  the	  breastfed	  infant.	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Global	  pandemic,	  approximately	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breastfeeding	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  and	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  infant	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Clinical	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Impact	  of	  breast	  milk	  transmission	  on	  




In	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  antenatal	  
HTLV-­‐1	  testing	  and	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Administration	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expressed	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  from	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  settings:	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  feeding	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LMIC:	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  post-­‐exposure	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  (currently	  
recommended	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  WHO	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longer	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  risk	  of	  MTCT	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Infant	  pre-­‐exposure	  prophylaxis	  (currently	  
not	  recommended	  by	  WHO)	  	  
Pasteurisation	  of	  breast	  milk	  (currently	  not	  
included	  in	  WHO	  guidelines)	  
Potentially,	  passive	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Role	  of	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uncertain	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PCR:	  Polymerase	  chain	  reaction;	  LMIC:	  Low-­‐	  and	  middle-­‐income	  countries;	  IgM:	  immunoglobulin	  M;	  sIgA:	  secretory	  immunoglobulin	  A;	  IgG:	  Immunoglobulin	  G;	  ATL:	  Adult	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